Keratin-5 (Keratin 5)

A type II keratin that is found associated with the KERATIN-14 in the internal stratified EPITHELIUM. Mutations in the gene for keratin-5 are associated with EPIDERMOLYSIS BULLOSA SIMPLEX.

Also Known As:

Networked: 409 relevant articles (8 outcomes, 34 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Akslen, Lars A: 8 articles (12/2007 - 10/2003)
2.	Ordóñez, Nelson G: 7 articles (07/2014 - 08/2003)
3.	Foulkes, William D: 6 articles (10/2008 - 10/2003)
4.	Weissferdt, Annikka: 5 articles (03/2015 - 07/2011)
5.	Moran, Cesar A: 5 articles (03/2015 - 07/2011)
6.	Wang, Xiao-Jing: 5 articles (12/2014 - 04/2004)
7.	Perou, Charles M: 5 articles (03/2008 - 12/2002)
8.	Stefansson, Ingunn M: 5 articles (03/2006 - 10/2003)
9.	Sartorius, Carol A: 4 articles (11/2015 - 07/2011)
10.	Koo, Ja Seung: 4 articles (02/2015 - 01/2010)

Related Diseases

1.	Carcinoma (Carcinomatosis) 02/01/2014 - "Although there was no significant difference in the frequency of expression of cytokeratin 5/6, p63, HER2, GATA3, and mammaglobin in cutaneous apocrine carcinoma versus mammary apocrine carcinoma, strong and diffuse cytokeratin 5/6 and/or mammaglobin expression were seen only in cutaneous apocrine carcinoma. " 11/01/2011 - "Reliability of the 34βE12, keratin 5/6, p63, bcl-2, and AMACR in the diagnosis of prostate carcinoma." 01/01/2010 - "Immunohistochemical identification of basal-like carcinomas is hindered with a fact, that on microarray level not all of them express basal-type cytokeratin 5/6, 14 and 17. " 09/01/2008 - "Ovarian carcinomas demonstrated D2-40 and cytokeratin 5/6 immunoreactivity in 23.2 and 55.4% of cases, respectively. " 08/01/2007 - "Immunophenotypic characterization of anal gland carcinoma: loss of p63 and cytokeratin 5/6."
2.	Neoplasms (Cancer) 01/01/2006 - "To study the role of E2F3 in tumor development, we established a transgenic mouse model expressing E2F3a in a number of epithelial tissues via a keratin 5 (K5) promoter. " 11/01/2015 - "Cytokeratin 5 expression correlated with ER positivity (38 of 42 CK5 tumors were also ER). " 03/01/2013 - "Antizyme (AZ) is a multifunctional negative regulator of cellular polyamine levels, and here, we evaluate the susceptibility of keratin 5 (K5)-AZ transgenic mice to tumor models that combine chemical carcinogenesis with dietary and genetic risk factors known to influence human susceptibility to UADT cancer and promote UADT carcinogenesis in mice. " 10/01/2012 - "We have previously described that in some ER(+) tumors, the resistant cells express cytokeratin 5 (CK5), a putative marker of breast stem and progenitor cells. " 09/01/2012 - "Nuclear immunoreactivity for WT1 or keratin 5 positivity was not detected in myofibroblastic tumors. "
3.	Adenocarcinoma 11/01/2012 - "In addition, anterior gradient homolog 2 and MUC5AC are useful positive markers of adenocarcinoma in the setting of absent or diminished p63 and cytokeratin 5/6 staining." 08/01/2007 - "Neoplastic basal cells and less-differentiated adenocarcinoma cells, which were identifiable by immunolabelling for cytokeratin 5 (CK5) and CK18, were considered to be pluripotential. " 12/01/2009 - "The purpose of this study was to determine whether SOX2 is differentially expressed in squamous cell carcinomas versus adenocarcinomas of the esophagus and rectum/anal canal and to compare its expression to p63, cytokeratin 5/6, and CDX2. " 08/01/1997 - "Previous studies using frozen material have suggested that cytokeratin 5 is expressed by pleural mesothelioma but not by adenocarcinoma. " 11/01/2012 - "Immunohistochemical panel for distinguishing esophageal adenocarcinoma from squamous cell carcinoma: a combination of p63, cytokeratin 5/6, MUC5AC, and anterior gradient homolog 2 allows optimal subtyping."
4.	Mesothelioma 08/01/2008 - "Cytokeratin 5/6 staining was also present in 33/34 (97%) of mesothelioma cases. " 06/01/2002 - "Cytokeratin 5/6 antibody, which recently became commercially available, has been found useful in the diagnosis of mesothelioma. " 05/01/2001 - "These results suggest that cytokeratin 5/6 is neither a sensitive nor specific stain for the diagnosis of mesothelioma in cytology material. " 08/01/1997 - "Anti-cytokeratin 5/6: a positive marker for epithelioid mesothelioma." 01/01/1989 - "Expression of keratin 5 as a distinctive feature of epithelial and biphasic mesotheliomas. "
5.	Noninfiltrating Intraductal Carcinoma (DCIS) 07/01/2006 - "Recent studies have demonstrated that immunohistochemical staining for cytokeratin 5/6 can distinguish UDH from conventional forms of ductal carcinoma in situ. " 05/01/2013 - "The immunohistochemical expression of cytokeratin 5/6 by ductal carcinoma in situ epithelial cells may provide clinically useful information regarding the risk of progression to invasive disease." 05/01/2013 - "In the low-grade ductal carcinoma in situ subgroup, only cytokeratin 5/6 expression exhibited a negative association with the probability of invasion. " 02/01/2007 - "A total of 245 pure ductal carcinoma in situ cases from a population-based, case-control study were evaluated for histologic characteristics and immunostained for ER, HER2/neu, EGFR, cytokeratin 5/6, p53, and Ki-67. " 07/01/2006 - "We tested the hypothesis that the results of staining for cytokeratin 5/6 can distinguish UDH from the solid papillary variant of ductal carcinoma in situ. "

Related Drugs and Biologics

1.	Antibodies
2.	calretinin
3.	Estrogens (Estrogen)
4.	Keratins (Keratin)
5.	Keratin-7 (Cytokeratin 7)
6.	Phenobarbital (Luminal)
7.	adjuvant P40 (P 40)
8.	Keratin-14 (Keratin 14)
9.	adipophilin
10.	Mucin-1 (CA 15-3 Antigen)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)